- Home
- ATHA vs DWTX Comparison
ATHA vs DWTX Comparison
Compare ATHA & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- DWTX
- Stock Information
- Founded
- ATHA 2011
- DWTX 2012
- Country
- ATHA United States
- DWTX United States
- Employees
- ATHA N/A
- DWTX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- DWTX
- Sector
- ATHA Health Care
- DWTX
- Exchange
- ATHA Nasdaq
- DWTX NYSE
- Market Cap
- ATHA 10.6M
- DWTX 9.2M
- IPO Year
- ATHA 2020
- DWTX N/A
- Fundamental
- Price
- ATHA $0.42
- DWTX $4.82
- Analyst Decision
- ATHA Buy
- DWTX Strong Buy
- Analyst Count
- ATHA 4
- DWTX 1
- Target Price
- ATHA $11.25
- DWTX $10.00
- AVG Volume (30 Days)
- ATHA 239.8K
- DWTX 28.7K
- Earning Date
- ATHA 07-31-2025
- DWTX 08-14-2025
- Dividend Yield
- ATHA N/A
- DWTX N/A
- EPS Growth
- ATHA N/A
- DWTX N/A
- EPS
- ATHA N/A
- DWTX N/A
- Revenue
- ATHA N/A
- DWTX N/A
- Revenue This Year
- ATHA N/A
- DWTX N/A
- Revenue Next Year
- ATHA N/A
- DWTX N/A
- P/E Ratio
- ATHA N/A
- DWTX N/A
- Revenue Growth
- ATHA N/A
- DWTX N/A
- 52 Week Low
- ATHA $0.22
- DWTX $1.62
- 52 Week High
- ATHA $3.67
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- ATHA 73.73
- DWTX N/A
- Support Level
- ATHA $0.29
- DWTX N/A
- Resistance Level
- ATHA $0.32
- DWTX N/A
- Average True Range (ATR)
- ATHA 0.03
- DWTX 0.00
- MACD
- ATHA 0.01
- DWTX 0.00
- Stochastic Oscillator
- ATHA 78.16
- DWTX 0.00
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.